awmsg logo



capecitabine (Xeloda®)


Reference No. 412

Publication date:
07/09/2011


Appraisal information

capecitabine (Xeloda®) 150 mg film-coated tablet
capecitabine (Xeloda®) 500 mg film-coated tablet


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/03/2011
AWMSG meeting date: 13/04/2011
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0511
Ministerial ratification: 01/09/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Capecitabine (Xeloda®) in combination with oxaliplatin is recommended as an option for use within NHS Wales for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer. Capecitabine (Xeloda®) is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download